Bob Lazarus is a Principal Scientist in the Department of Early Discovery Biochemistry at Genentech, Inc. He joined Genentech in 1983 after receiving his Ph.D. in Chemistry (1979) and carrying out postdoctoral research from Penn State University. He served as the Secretary and then President of the International Proteolysis Society from 2011-2015. Dr. Lazarus has explored protein engineering and mechanistic enzymology projects to investigate molecular, biochemical and biological aspects of protein/protein and protein/ligand interactions. His research areas have included tryptase inhibitors for asthma, HGF/Met receptor tyrosine kinase signal transduction implicated in tumorigenesis, metastasis and tissue repair, BACE1 inhibitors for Alzheimer’s disease, the Hedgehog pathway of developmental biology and cancer, molecular diversity scaffolds by phage display, improved versions of DNase I with increased enzymatic activity for CF and other diseases, exosite inhibitors of coagulation Factor VIIa as protease inhibitors and anticoagulants, Kunitz domains as scaffolds for protease inhibition, GPIIb-IIIa integrin antagonists from snake venoms and leeches as platelet aggregation inhibitors and microbial pathway engineering for bioconversion of glucose to vitamin C.